Resilience entered into a strategic collaboration with Labcorp to establish a joint customer service offering that provides an end-to-end solution for the preclinical, clinical development and commercial manufacturing of cell and gene therapies (CGT).

The collaboration aims to provide streamlined planning with greater flexibility and shared expertise across the drug development continuum and reduced risk of repeat activities.

Resilience and Labcorp will jointly work with customers to evaluate and chart an efficient path to the first-in-human trials and/or advancement from clinical trials through commercial approval.

The aim is to enable expedited timelines, cost savings and mitigation of risks for preclinical, clinical, and commercial activities.

Together, the companies will provide customized expertise to address critical challenges at any and every stage of CGT development. Labcorp will focus on preclinical and clinical development, laboratory, and commercialization services. Resilience will focus on manufacturing process development, process technology scale-up/out and technology transfer, and GMP manufacturing solutions and services.

In addition, the collaboration presents a unique opportunity to simplify customer supply chains, accelerate drug development and reduce development costs.

By combining Labcorp’s cell and gene therapy solutions with Resilience’s CGT manufacturing science and technologies, the company said that it has the opportunity to enhance and accelerate CGT development.